Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CTMX | CytomX Therapeutics Inc

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	2.02%	Shs Outstand	66.23M	Perf Week	-6.67%
Market Cap	84.13M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	-1.70%	Shs Float	65.42M	Perf Month	-13.70%
Income	-36.47M	PEG	-	EPS next Q	-0.19	Inst Own	51.16%	Short Float / Ratio	3.31% / 7.94	Perf Quarter	-10.64%
Sales	85.26M	P/S	0.99	EPS this Y	69.21%	Inst Trans	-19.56%	Short Interest	2.17M	Perf Half Y	-29.61%
Book/sh	-1.27	P/B	-	EPS next Y	-76.27%	ROA	-15.54%	Target Price	2.49	Perf Year	-11.89%
Cash/sh	2.71	P/C	0.47	EPS next 5Y	-0.90%	ROE	-4417.92%	52W Range	1.17 - 3.02	Perf YTD	-21.25%
Dividend	-	P/FCF	-	EPS past 5Y	-5.43%	ROI	-	52W High	-58.28%	Beta	0.68
Dividend %	-	Quick Ratio	1.33	Sales past 5Y	6.79%	Gross Margin	92.96%	52W Low	7.69%	ATR	0.06
Employees	116	Current Ratio	1.33	Sales Q/Q	36.11%	Oper. Margin	-40.76%	RSI (14)	23.29	Volatility	4.61% 4.10%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	95.58%	Profit Margin	-42.77%	Rel Volume	0.27	Prev Close	1.26
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 08 AMC	Payout	-	Avg Volume	272.93K	Price	1.26
Recom	3.11	SMA20	-9.45%	SMA50	-18.96%	SMA200	-30.70%	Volume	73,037	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$3 → $2.60
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral	$6 → $2
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $1.50
Jul-07-22	Downgrade	Mizuho	Buy → Neutral	$16 → $4
Jul-07-22	Downgrade	Jefferies	Buy → Hold	$12 → $2
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$9
Jan-18-22	Upgrade	Barclays	Underweight → Overweight	$7
Nov-15-21	Initiated	BTIG Research	Buy	$16
May-28-21	Downgrade	Barclays	Equal Weight → Underweight	$9 → $7
Mar-29-21	Initiated	JP Morgan	Overweight	$14
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold	$16 → $10
May-14-20	Reiterated	H.C. Wainwright	Buy	$16 → $12
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight	$7
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral	$25 → $8
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight	$21

Show Previous Ratings

Sep-05-23 04:05PM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) -5.33%
Aug-25-23 09:35AM	CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-10-23 04:05PM	CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-08-23 05:30PM	CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	CytomX Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:15PM	Loading…
04:15PM	CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 08:00AM	CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-20-23 09:00AM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-17-23 08:00AM	CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (GlobeNewswire)
Jun-30-23 08:00AM	CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P. (GlobeNewswire) +21.99%
Jun-08-23 09:02AM	CytomX Therapeutics (NASDAQ:CTMX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-01-23 04:05PM	CytomX Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 06:05AM	CytomX Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 08:13AM	Q1 2023 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +5.81%
May-09-23 05:35PM	CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Loading…
04:26PM	CytomX Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:15PM	CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-05-23 06:34AM	CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-01-23 04:01PM	CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire) +5.52%
10:01AM	Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-27-23 10:03AM	Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-25-23 04:05PM	CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-30-23 11:26AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 06:06AM	What Does The Future Hold For CytomX Therapeutics, Inc. (NASDAQ:CTMX)? These Analysts Have Been Cutting Their Estimates (Simply Wall St.)
Mar-28-23 01:35PM	AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners (Benzinga) -15.08%
Mar-27-23 05:35PM	CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.29%
04:15PM	CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-22-23 07:23PM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 (GlobeNewswire)
Mar-20-23 06:14AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 42% of the company (Simply Wall St.)
Feb-28-23 04:05PM	CytomX Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
06:07AM	Loading…
Feb-07-23 06:07AM	Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago (Simply Wall St.)
Jan-26-23 07:00AM	CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire) +6.11%
Jan-17-23 04:05PM	CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference (GlobeNewswire) -6.64%
Jan-12-23 05:30AM	An Intrinsic Calculation For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Suggests It's 38% Undervalued (Simply Wall St.)
Jan-06-23 06:44PM	AbbVie cuts earnings forecast due to milestone payments (MarketWatch) +40.78%
01:46PM	CytomX (CTMX) Up 55% on Strategic Partnership With Moderna (Zacks)
10:30AM	CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker (Benzinga)
Jan-05-23 05:11PM	CytomX shares surge more than 50% on Moderna partnership (MarketWatch) +7.19%
04:19PM	Moderna signs $35 million deal with cancer drug developer CytomX (Reuters)
04:05PM	CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities (GlobeNewswire)
04:05PM	CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics (GlobeNewswire)
Dec-22-22 05:00PM	CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023 (GlobeNewswire)
07:54AM	We're A Little Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate (Simply Wall St.)
Dec-20-22 05:00PM	CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-22 04:30PM	CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-23-22 12:18PM	Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update (Zacks) -6.28%
Nov-18-22 01:18PM	CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron (Zacks) +8.75%
Nov-17-22 11:14AM	CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron (Benzinga) +32.23%
11:09AM	Peninsula biotech moves from layoffs to cancer-fighting deal with potential $2B payoff (American City Business Journals)
07:00AM	Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (PR Newswire)
07:00AM	CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (GlobeNewswire)
Nov-08-22 05:35PM	CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:10PM	CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 04:15PM	CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting (GlobeNewswire)
Nov-02-22 04:15PM	CytomX Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-22 08:00AM	CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire)
Oct-27-22 05:15PM	Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Sep-13-22 08:42AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners may be pleased with recent gains after 68% loss over the past year (Simply Wall St.)
Sep-12-22 08:00AM	CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249 (GlobeNewswire) +6.88%
Sep-07-22 06:05PM	CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051 (GlobeNewswire)
Sep-01-22 10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-05-22 08:30AM	CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 05:45PM	CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:15PM	CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-22 08:00AM	CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences (GlobeNewswire)
Aug-01-22 10:01AM	ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-28-22 10:02AM	CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-15-22 10:50AM	Peninsula biotech CytomX laying off 40% of workforce after clinical trial flop (American City Business Journals) +7.14%
07:54AM	Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-14-22 06:05AM	CytomX Therapeutics Cuts Workforce, Extend Cash Runway Into 2025 (Benzinga) +7.69%
Jul-13-22 04:05PM	CytomX Therapeutics Provides Strategic Update (GlobeNewswire)
Jul-07-22 06:15AM	CytomX's Breast Cancer Candidate Meets Primary Goal Of Objective Response Rate (Benzinga) -37.56%
Jul-06-22 04:05PM	CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer (GlobeNewswire)
Jun-27-22 08:33AM	NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-16-22 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jun-01-22 08:00AM	CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference (GlobeNewswire)
May-26-22 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire)
May-07-22 08:11AM	Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago (Simply Wall St.)
May-06-22 10:30PM	CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript (Motley Fool)
May-05-22 06:25PM	CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.85%
04:15PM	CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-22 08:00AM	CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022 (GlobeNewswire)
Apr-14-22 04:15PM	CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors (GlobeNewswire)
Apr-06-22 06:47AM	What Kind Of Shareholders Hold The Majority In CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares? (Simply Wall St.)
Mar-23-22 04:15PM	CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors (GlobeNewswire)
Mar-17-22 08:00AM	CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022 (GlobeNewswire) +15.67%
Mar-02-22 01:00AM	CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript (Motley Fool) +14.12%
Mar-01-22 05:45PM	CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -7.57%
04:15PM	CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update (GlobeNewswire)
Feb-28-22 05:15PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:00AM	CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference (GlobeNewswire)
Feb-22-22 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022 (GlobeNewswire)
Feb-16-22 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Feb-07-22 09:00AM	CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer (GlobeNewswire)
Feb-05-22 08:05AM	Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jan-26-22 08:15AM	Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Jan-20-22 10:41AM	CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors (Zacks)
08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-19-22 08:00AM	CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors (GlobeNewswire) +6.53%

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCarthy Sean A.	CEO	Sep 22	Sale	1.30	14,601	18,987	430,755	Sep 22 07:13 PM
ROWLAND LLOYD A	General Counsel	Sep 22	Sale	1.30	5,486	7,135	80,609	Sep 22 07:12 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Sep 22	Sale	1.30	4,119	5,356	147,951	Sep 22 07:16 PM
Landau Jeffrey B	Chief Business Officer	Sep 22	Sale	1.30	4,119	5,356	76,379	Sep 22 07:15 PM
McCarthy Sean A.	CEO	May 19	Option Exercise	1.57	16,535	26,041	405,356	May 23 04:52 PM
Jones Elaine V	Director	Mar 29	Buy	1.55	5,000	7,750	5,142	Mar 31 07:56 PM
McCarthy Sean A.	CEO	Mar 16	Sale	1.88	7,121	13,391	388,821	Mar 20 06:43 PM
Peterson Amy C.	EVP, Chief Development Officer	Mar 16	Sale	1.98	4,257	8,425	58,433	Mar 20 06:43 PM
ROWLAND LLOYD A	General Counsel	Mar 16	Sale	1.98	2,037	4,031	71,095	Mar 20 06:43 PM
Campoy Carlos	Chief Financial Officer	Mar 16	Sale	1.98	1,748	3,459	38,224	Mar 20 06:43 PM
Landau Jeffrey B	Chief Financial Officer	Mar 16	Sale	1.98	1,477	2,923	69,248	Mar 20 06:43 PM
Ogden Christopher	SVP, Finance and Accounting	Mar 16	Sale	1.98	516	1,021	37,772	Mar 20 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTMX | CytomX Therapeutics Inc

Upgrade your FINVIZ experience